| |
 |
| Online: |
| ¬ User: 0 |
| ¬ Gäste: 27 |
| Besucher: |
| ¬ Heute: 970 |
| ¬ Gestern: 1209 |
| ¬ Gesamt: 2119950 |
| ¬ ø Tag: 249.17 |
| Max.: |
| ¬ pro Tag: 3598 |
| ¬ Online: 540 |
| |
|
 |
|
|
|
| Forum |
| » Hauptforum » Forum: Call of Duty » Thread: Bimatoprost was not mutagenic or clastogenic in th |
| |
| [ Neuer Eintrag - letzter Post ] |
| Thread |
 Seite: « 1 » |
| #1 |
» 19.10.17 09:11h |
lily  |
 |
| User |
| Posts: 419 |
|
|
Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests. Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (approximately 103 times the recommended human exposure based on blood AUC levels). Pregnancy: Teratogenic Effects: Pregnancy Category C. In embryo/fetal developmental studies in pregnant mice and rats, abortion was observed at oral doses of bimatoprost, which achieved at least 33 or 97 times, respectively, the intended human exposure based on blood AUC levels. lumigan generic received FDA approval in 2001 for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.The FDA suggested that patients who use bimatoprost cosmetically in conjunction with topical lumigan bimatoprost may be at risk for increased optic nerve damage because the extra dose would, in fact, decrease the drugs effectiveness.?Additionally, the FDA cited the potential for other adverse effects in certain people using the product, including macular edema. At doses 41 times the intended human exposure based on blood AUC levels, the gestation length was reduced in the dams, the incidence of dead fetuses, late resorptions, peri- and postnatal pup mortality was increased, and pup body weights were reduced. |
-> last edit by lily 19.10.2017 09:12h |
|
| |
 |
|
|
| Seite: « 1 » |
| [ Neuer Eintrag - letzter Post ] |
|
 |
|
|
vs. sf-c
33:15
8:40
vs. GD
halflife2